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Background When used correctly, dermoscopy is an essential tool for helping clini-
cians in the diagnosis of skin diseases and the early detection of skin cancers.
Despite its proven benefits, there is a lack of data about how European dermatol-
ogists use dermoscopy in everyday practice.
Objectives To identify the motivations, obstacles and modifiable factors influencing
the use of dermoscopy in daily dermatology practice across Europe.
Methods All registered dermatologists in 32 European countries were invited to
complete an online survey of 20 questions regarding demographic and practice
characteristics, dermoscopy training and self-confidence in dermoscopic skills,
patterns of dermoscopy use, reasons for not using dermoscopy and attitudes
relating to dermoscopy utility.
Results We collected 7480 valid answers, of which 89% reported use of der-
moscopy. The main reasons for not using dermoscopy were lack of equipment
(58% of nonusers) and lack of training (42%). Dermoscopy training during resi-
dency was reported by 41% of dermoscopy users and by 12% of nonusers
(P < 0001). Dermatologists working in public hospitals were the least likely to
use dermoscopy. High use of dermoscopy across the spectrum of skin diseases
was reported by 62% of dermoscopy users and was associated with dermoscopy
training during residency, the use of polarized light and digital dermoscopy
devices, longer dermoscopy practice, younger age and female gender.
Conclusions Expanding access to dermoscopy equipment, especially in public
healthcare facilities and establishing dermoscopy training during dermatology res-
idency would further enhance the substantially high dermoscopy use across Euro-
pean countries.
What’s already known about this topic?
• Dermoscopy is a well-established tool for the noninvasive diagnosis of skin diseases.
• The benefits of dermoscopy depend on correct use by trained physicians.
• Although considered to be widely used in Europe, reports on dermoscopy use by
dermatologists have been carried out in only two European countries so far.
What does this study add?
• Our study is the first pan-European survey of dermatologists regarding the patterns
of use, training and attitudes towards dermoscopy.
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• We report on the demographic, practice- and training-related factors driving or
hampering the use of dermoscopy in the daily practice of dermatologists in 32
European countries.
Dermoscopy has become an essential tool for the early detec-
tion of skin cancers and noninvasive dermatological diagno-
sis.1,2 It is considered to be widely used in Europe; however,
reports on dermoscopy use by dermatologists have been car-
ried out in only two European countries so far,3–5 compared
with broader analysis in Australia6,7 and the U.S.A.8–11
While skin cancer incidence continues to rise, important dif-
ferences in skin cancer burden have been reported across
Europe,12–15 with late diagnosis, underdiagnosis and poorer
prognosis reported in many Central and Eastern European coun-
tries.12,16 Moreover, it is estimated that half of the worldwide
melanoma deaths occur in European countries. Dermoscopy, as
an established, easy-to-use and accessible technique of in vivo
skin visualization, may contribute towards improving early
detection of skin cancers and alleviating these disparities.
Dermoscopy has evidence-confirmed benefits for increasing
the accuracy of skin cancer diagnosis. It increases clinicians’
accuracy in melanoma detection1,17–19 and can reduce the
number of unnecessary biopsies of benign lesions.20–23 Der-
moscopy also supports the in vivo differentiation of a wide
range of pigmented and nonpigmented skin tumours,24,25 and
its role in distinguishing neoplastic from inflammatory lesions
is expanding.26–28 Consequently, dermoscopy is considered
the standard of care for skin cancer diagnosis and monitoring
of high-risk groups and is included in the current clinical
practice guidelines worldwide.29–32 Yet its benefits depend on
correct use by experienced and trained physicians.18 Thus, it
is important to understand the patterns of dermoscopy use
across Europe, the obstacles to its optimal use and the path-
ways by which this technique could be made available for a
wider proportion of European dermatologists in order to
enhance the noninvasive diagnosis of skin diseases.
Towards this goal, we conducted the first pan-European
analysis of the use of dermoscopy by dermatologists, seeking
information on the motivations, barriers and modifiable fac-
tors related to the use of dermoscopy in the daily practice
across the continent.
Materials and methods
The study consisted of a survey of European dermatologists,
conducted under the auspices of the International Dermoscopy
Society (IDS).
Study instrument
The study questionnaire was developed by the study’s task
force experts (G.A., A.M.F., H.P.S., I.Z., A.C.G. and V.M.), in
agreement with the IDS guidelines and literature-reported
practices.5,7 The questionnaire comprised a core of 20
multiple-choice questions (Appendix S1; see Supporting Infor-
mation) regarding demographic and practice characteristics,
dermoscopy training and use patterns, opinions about der-
moscopy utility and self-reported confidence in dermoscopic
diagnosis. The questionnaire excluded personal identification
questions and was translated into the languages of all partici-
pant countries.
Study participants
The study was intended for all licensed dermatologists regis-
tered in European countries defined by the United Nations
Organization classification.33 In each participating country, a
National Coordinating Team (NCT), led by a National Coordi-
nator (NC), took the responsibility of implementing the study,
collaborating with national dermatology and dermoscopy pro-
fessional associations. NCs were members of the IDS Board of
Directors, or Country Coordinators of the Euromelanoma cam-
paign34 for the countries without an IDS Board representative.
The responsibilities of the NCs included accessing the national
databases of dermatologists, obtaining the necessary study
approvals at national level, communicating the number of der-
matologists officially registered in the country, survey transla-
tion, survey dissemination solely to registered dermatologists
nationwide, motivating dermatologists to participate, collect-
ing offline responses and participating in the reporting of
study results.
Participating countries
A total of 39 countries in the Europe region33 were invited to
participate and three additional countries (Turkey, Israel and
Georgia) joined the study as part of the Council of Europe.35
An effective National Coordination was established in 33
countries; one country (Ukraine) could not complete the
study owing to political instability. A total of 32 countries
completed the study and data from the following countries
are included in the present analysis: Austria, Belgium, Belarus,
Bosnia-Herzegovina, Bulgaria, Czech Republic, Croatia, Esto-
nia, France, Germany, Georgia, Greece, Hungary, Ireland,
Israel, Italy, Latvia, Lithuania, the former Yugoslav Republic of
Macedonia, Norway, the Netherlands, Portugal, Romania, Rus-
sia, Serbia, Slovenia, Slovak Republic, Spain, Sweden, Switzer-
land, Turkey and the U.K.
Survey dissemination
Survey dissemination occurred through the IDS web-based
platform for online surveys. For each participating country a
dedicated webspace was created, accessible by a
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country-specific link and containing the electronic survey
translated in the country’s language. The country access link
was communicated by each NC to all registered dermatologists
in the respective national database. NCTs had the option to
use additional offline methods for survey dissemination (post,
e-mail, etc.) fulfilling the study criteria, i.e. anonymity,
restriction to nationally registered dermatologists and avoid-
ance of duplicate responses. Slovenia and Lithuania conducted
the survey offline only. Offline data were introduced manually
into electronic databases using Microsoft Excel (Microsoft Cor-
poration, Redmond, WA, U.S.A.) by the respective NCTs, veri-
fied by a study task force member and merged with the
central study database.
Survey collection
Dermatologists in each country used the country-specific link
to access the online questionnaire and were instructed to com-
plete the survey only once. The survey was anonymous and
only responders answering ‘yes’ to Question 9 (‘Do you use
dermoscopy?’) could proceed to later questions regarding the
practice of dermoscopy use. The IDS online survey platform
was open between 1 July 2014 and 1 December 2014, during
which period NCTs sent four reminders to all dermatologists
in their contact databases. Online responses were collected in
an access-restricted central database, grouped by country
access code. They were subsequently merged with the elec-
tronic databases of offline responses transmitted by the NCTs.
Data processing
Data cleaning of the study database was performed by three
independent investigators (A.M.F., P.T. and G.G.) who elimi-
nated empty entries, duplicate entries (same IP address, sex,
age, practice settings), technical error entries and invalid
answers defined as missing or unrealistic answers in any of
Questions 1–8.
Statistical analysis
Answers to Questions 1–18 are analysed in the present work.
Continuous data are given as mean and SD unless stated other-
wise, and parametric tests for comparing groups were used
only if corresponding assumptions were met. Comparing pro-
portions of two groups v2-test and comparing proportions of
ordered groups v2-test for trends in proportions were used.
For multivariate analysis all variables that were significant in
the univariate analysis were entered using a model with back-
wards elimination, controlled for sex, age, years in practice
and numbers of patients with skin cancer and overall number
of patients seen per month. Remaining predictors are given as
odds ratios with 95% confidence intervals. Questions regard-
ing confidence in using dermoscopy and advantages of der-
moscopy were rated on a 3-point Likert scale. To differentiate
‘high’ dermoscopy users from ‘low’ dermoscopy users, a score
was created by summarizing levels of percentages of indicated
use in the three categories of inflammatory, pigmented and
nonpigmented skin lesions (Question 15), where a score of
between 1 and 5 points could be obtained in every category.
The summarized score could range from 3 to 15 points, and
was separated into two groups (‘high’ and ‘low’ users) by k-
means clustering. Those who reached the cut-off of 11 points
were classified as ‘high users’ who used dermoscopy in at
least two application fields more than 50% of the time.
A P < 005 was regarded as statistically significant; in uni-
variate analysis P-values were adjusted using the method
described by Holm.36 All statistical computation and genera-
tion of graphics were performed using R (https://www.
r-project.org) with the packages ggplot237 and Likert
(https://cran.r-project.org/package=likert).
Results
The study included 32 European countries, in which a total
number of 38 300 dermatologists were registered by the rele-
vant national health authorities, as reported by the NCTs. A
total of 8297 online responses and 222 offline responses were
collected. The response rate, defined as the proportion of
respondents divided by the total number of certified dermatol-
ogists in each country, ranged from 7% to 697% and had a
median value of 332% for all participating countries. After
data cleaning, a total of 7480 valid responses were maintained
for analysis.
Factors associated with use of dermoscopy by European
dermatologists
The majority of respondents were women (69%), and the
mean age was 467 years. Overall, 89% of respondents
reported using dermoscopy, with a slightly lower proportion
of women in the dermoscopy users group (68% vs. 79%,
P < 0001). In the univariate analysis and multivariate analy-
sis, using dermoscopy was significantly associated with the
following: working in a private individual practice or in a uni-
versity hospital, involvement in teaching activities, higher
number of patients and higher number of patients with skin
cancer seen monthly (Table 1). Dermoscopy users reported
having received dermoscopy training during residency more
frequently than nonusers of dermoscopy (41% vs. 12%,
P < 0001) and also having received any type of other der-
moscopy training. Almost 50% of nonusers reported that they
had not received any type of dermoscopy training. Working
in public healthcare facilities was associated with a lower rate
of dermoscopy use.
Reasons for not using dermoscopy
Among the 822 dermatologists not using dermoscopy, the
main reasons for not using this technique were the lack of
equipment (not available or too expensive) and a lack of edu-
cation (no dermoscopy training or not being confident in
their own dermoscopy skills) (Fig. 1). Cost played a lesser
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role (17%) and reimbursement did not appear to be impor-
tant. The vast majority of those not using dermoscopy (98%)
still regarded it as a useful technique.
When the results were stratified by practice setting, the
most common reason for not using dermoscopy given by der-
matologists working in individual private practices and public
healthcare facilities was the lack of equipment (Fig. S1; see
Supporting Information).
Factors related to high use of dermoscopy
Almost two-thirds of all dermoscopy users (62%) were also
‘high users’ of dermoscopy (as defined above). In the univari-
ate analysis (Tables 2 and 3), high use of dermoscopy was
significantly associated with slightly lower age and shorter
duration of dermatology specialist practice, working in indi-
vidual private practice, a higher number of patients with skin
Table 1 Factors associated with the use of dermoscopy
Dermoscopy users Nonusers P-value
P-value
(multivariate)a
N = 7424 6602 (8892) 822 (1108)
Female participants 4442 (6766) 643 (788) < 0001 0001
Age, years, mean (SD) 4695 (1101) 437 (1196) < 0001
Place of work
Individual private practice 2517 (3812) 141 (1715) < 0001 0001
Private ambulatory/hospital 1340 (2030) 205 (2494) 0060
Public ambulatory/hospital 2026 (3069) 440 (5353) < 0001 < 0001
University hospital 1387 (2101) 78 (949) < 0001 0011
Involved in teaching activity for
dermatology residents
844 (1278) 71 (864) 0021
No. of years as a dermatologist,
mean (SD)
1617 (1072) 1492 (1098) 0063
No. of patients seen per month,
mean (SD)
43321 (40558) 27591 (29429) < 0001 < 0001
No. of patients with skin cancer
seen per month, mean (SD)
5865 (10711) 885 (3933) < 0001 < 0001
Dermoscopy training during residency 2709 (4164) 97 (1202) < 0001 < 0001
Types of dermoscopy training outside of residency
Dermoscopy course 4162 (6304) 120 (1460) < 0001 < 0001
Online dermoscopy course 1202 (1821) 41 (499) < 0001 < 0001
Attended conferences congresses 4721 (7151) 213 (2591) < 0001 < 0001
Books and atlases 5289 (8011) 268 (3260) < 0001 < 0001
Mentor tutor 1537 (2328) 58 (706) < 0001 < 0001
No training 220 (333) 395 (4805) < 0001 < 0001
Overall, 56 of 7480 participants gave no valid answer to the grouping Question 9 (Do you use dermoscopy?). aVariables without a P-value
in this column were not significant in multivariate analysis and were not entered to the model as they did not improve the regression model.









It is too time consuming 
I do not consider it useful for my practice 
It is not well reimbursed 
Other  
The equipment is too expensive 
I am not confident enough in my skills 
I have not been trained  in dermoscopy 
A dermoscope is not available in my office 
0% 20% 40% 60%
% of answers
Fig 1. Reasons for not using dermoscopy reported by European dermatologists.
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cancer seen per month, having received dermoscopy training
during residency, and having received any type of dermoscopy
training. Dermatologists reporting high use of dermoscopy
were more likely to report the use of polarized light devices
or digital dermoscopy devices compared with low users of
dermoscopy, and were more likely to use pattern analysis or
no predefined dermoscopic algorithm. High use was also asso-
ciated with a longer duration of dermoscopy practice, with
positive views on dermoscopy and with higher confidence in
diagnostic skills across all categories of skin lesions (Table S1;
see Supporting Information).
The overall number of patients seen or the use of contact
immersion dermoscopy did not differ significantly between
high and low users of dermoscopy. Working in public hospi-
tals (except university hospitals) was associated with lower
use of dermoscopy.
For both high and low users of dermoscopy, the education
methods most frequently reported outside residency training
were books and atlases (83% and 76%, respectively), followed
by attending conferences and formal dermoscopy courses. A
smaller proportion of high and low users (26% and 19%,
respectively) benefited from having a mentor or tutor teach-
ing, and up to one-fifth took advantage of online courses.
In the multivariate analysis, high use of dermoscopy
remained significantly associated with female gender, having
received online dermoscopy training, using polarized light
and digital video-dermoscopy systems, longer practice, with
using pattern analysis but not the ABCD rule (Tables 2 and 3)
and also with a positive opinion about the benefits of der-
moscopy and self-confidence in their dermoscopic diagnosis
skills required for detecting nonpigmented skin tumours
(Table S1; see Supporting Information).
Discussion
This study is the first pan-European analysis of the patterns of
dermoscopy use by dermatologists. With 7500 responses, rep-
resenting one in every five dermatologists registered in 32
European countries, this is the largest survey to date and it
offers a unique view of the factors modulating the use of this
technique across the continent. Thus, it provides a valuable
knowledge base for future strategies to enhance the use of
dermoscopy towards achieving improved diagnosis of skin
diseases and early detection of skin cancers in Europe.
While recognizing the limitations of a lack of response from
many European dermatologists, our study suggests that der-
moscopy is well-established in dermatology practice across
Europe. Still, 11% of participating dermatologists do not use
dermoscopy, a proportion higher than that previously
reported.4,5 Notably, the main reasons for not using der-
moscopy include the lack of education and equipment, but
not the lack of time, interest for the technique or financial







N = 6118 3830 (6260) 2288 (3740)
Female participants 2594 (6807) 1487 (6528) 0162 0016
Age, years, mean (SD) 463 (1074) 4809 (SD: 1132) < 0001
Place of work
Individual private practice 1606 (4193) 750 (3278) < 0001
Private ambulatory/hospital 722 (1885) 488 (2133) 0142
Public ambulatory/hospital 1092 (2851) 766 (3348) < 0001
University hospital 819 (2138) 495 (2163) 1000
Involved in teaching activity for
dermatology residents
502 (1311) 290 (1267) 1000
Years as dermatology specialist,
mean (SD)
1539 (1049) 1742 (1095) < 0001
No. of patients seen per month,
mean (SD)
44486 (39528) 42718 (42072) 0428
No. of patients with skin cancer
seen per month, mean (SD)
6674 (11787) 4925 (9255) < 0001 0033
Dermoscopy training during residency 1727 (4563) 810 (3589) < 0001
Types of nonresidency dermoscopy training
Dermoscopy course 2581 (6739) 1323 (5782) < 0001
Online dermoscopy course 809 (2112) 326 (1425) < 0001 0025
Attended conferences congresses 2901 (7574) 1533 (6700) < 0001
Books and atlases 3186 (8319) 1753 (7662) < 0001
Mentor tutor 1003 (2619) 431 (1884) < 0001
No training 97 (253) 100 (437) 0001
aVariables without a P-value in this column were not significant in multivariate analysis and were not entered into the model as they did not
improve the regression model. Continuous data are given as mean with SD, proportions as n (%).
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incentives. This is in sharp contrast with other reports4,5,8 and
is based on a significantly large sample, suggesting that
improving education and access to equipment could enhance
the use of dermoscopy by European dermatologists.
The importance of education for enhancing the use of der-
moscopy was a main finding of our study, confirming the
insights from previous national reports on a pan-European
scale.4,5,8,10 Half of dermatologists who did not use der-
moscopy had not received any training in dermoscopy, and a
lack of training and confidence in their own dermoscopy skills
were among the main reasons for not using dermoscopy.
Access to dermoscopy education was also an important factor
associated with high use of dermoscopy compared with low
use. Residency dermoscopy training appeared to be particu-
larly important in distinguishing dermoscopy users vs. nonu-
sers and high users vs. low users. As less than 40% of all
respondents reported dermoscopy training during residency,
this is an area where improvement is needed towards achiev-
ing a harmonized, high-standard education of dermatologists
across Europe in order to comply with current practice guide-
lines,29–32 where dermoscopy becomes the standard of care.
Practice setting was another noteworthy factor influencing
the use of dermoscopy in Europe. Both nonusers and low
users of dermoscopy were more likely to work in public
healthcare facilities than in other settings. In contrast, derma-
tologists working in individual practices were the most likely
to use dermoscopy. The reasons for these differences require
further exploration. The lack of available equipment may play
a role, as this was a common reason given by physicians who
did not use dermoscopy and worked in public healthcare facil-
ities. A lack of training or workload, as reasons for not using
dermoscopy, did not appear to differ between private or pub-
lic practice settings (P = 0154). Overall, dermoscopy users
reported a much higher number of patients seen per month
than nonusers (Table 1), and there was no significant differ-
ence between the number of patients seen monthly by high
users vs. low users.
Dermoscopy users in general, and high users in particular,
saw more patients with skin cancer per month and were most
confident in their diagnostic skills for pigmented skin
tumours. This suggests that the main use of dermoscopy
remains related to the diagnosis of melanoma and skin can-
cers. At the other end of the spectrum, inflammatory lesions
(for which dermoscopy use is still under exploration and stan-
dardization)27,28 was the category in which dermoscopy was
used least often, its benefits were perceived to be lower and
the lowest self-confidence was expressed by a considerable
proportion of responders.
Many algorithms exist to facilitate the dermoscopic diagno-
sis of skin lesions, particularly for melanoma.38–40 In our
study, it was interesting to find that use of the classic ABCD
algorithm was reported mostly by low users of dermoscopy
(37%), while pattern analysis was favoured by high users
(35%). Roughly one-third of respondents in both high-use
and low-use categories reported not using any algorithm in
particular.







N = 6118 3830 (6260) 2288 (3740)
No. of years using dermoscopyb
< 2 years 284 (745) 360 (1580) < 0001 < 0001
2–5 years 710 (1863) 506 (2220)
> 5 years 2818 (7392) 1413 (6200)
Types of dermoscopes used
Nonpolarized immersion contact 2025 (5287) 1266 (5533) 0328
Polarized light dermoscope 2223 (5804) 1050 (4589) < 0001 0021
Dermoscope with digital camera 961 (2509) 422 (1844) < 0001
Digital videodermatoscopy system 1174 (3065) 424 (1853) < 0001 0012
Average frequency of using dermoscopyb
Less than once per month 10 (026) 37 (162) < 0001 < 0001
1–4 times per month 62 (162) 185 (810)
More than once per week 244 (639) 406 (1778)
Daily 3501 (9172) 1655 (7249)
Regularly used dermoscopic algorithm 0597
ABCD rule 1018 (2658) 841 (3676) < 0001 0001
CASH 22 (057) 17 (074) 1000
Menzies algorithm 107 (279) 51 (223) 0825
Seven-point check list 331 (864) 155 (677) 0093
Pattern analysis 1338 (3493) 522 (2281) < 0001 < 0001
I do not systematically use any particular algorithm 1057 (2760) 721 (3151) 0012
CASH: Colour, Architecture, Symmetry and Homogeneity. aVariables without a P-value in this column were not significant in multivariate
analysis and were not entered into the model as they did not improve the regression model. bVariables with a calculated linear correlation in
multivariate analysis.
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Contact immersion dermoscopy and polarized light der-
moscopy appeared to be used with equal frequency by Euro-
pean dermatologists, and about 37% of responders reported
using a digital dermoscopy device. As digital photo or video-
dermoscopy systems are essential for monitoring melanocytic
lesions and monitoring patients with a risk of
melanoma,17,41–43 these results suggest that a minority of der-
matologists who use dermoscopy are equipped for the proper
management of skin cancer and high-risk patients.
The demographics of our respondents were comparable
with similar surveys, with a majority of female responders,
likely reflecting the higher proportion of female physicians in
dermatology practice worldwide. The mean age of our
responders across Europe was lower than reported in France
and the U.K.,4,5 and dermoscopy use was not associated with
younger age in our study, likely reflecting the heterogeneity
in the age distribution and training of dermatologists among
European countries.
Our study has several limitations inherent to its design and
proportions. The representativeness and possible selection bias
are issues common to all similar studies. We chose to report
the number of responders relative to the total number of der-
matologists officially registered in the participating countries,
and not to the number of dermatologists contacted, in order
to have a reliable parameter for assessing the penetrance and
representativeness of our survey. As the inclusion of dermatol-
ogists in different professional associations or contact databases
varied significantly among countries, we considered that the
official number of dermatologists issued by the health author-
ity is a more informative denominator for our analysis. Using
this definition, we reached a median response rate of 33% of
all dermatologists in the participating countries. Similar studies
on a national scale had a response rate of 22% of British Asso-
ciation of Dermatologists4 and 496% of all registered private
dermatologists in France.5 Obtaining more than 8000 surveys
reflects not only the interest that European dermatologists have
in dermoscopy, but also the strong commitment of the NCTs
to reach and motivate the responders, and the effectiveness of
the methodology.
It may be argued that a survey of this type is more likely
to be answered by dermoscopy users than nonusers or fre-
quent users of dermoscopy rather than sporadic users.
Nonetheless, we received surveys from more than 800 nonu-
sers and many more sporadic users. Our analysis takes the
pan-European view, as mobility of patients, physicians and
trainees, coupled with the common historical and political
framework, unites European countries in facing common
challenges in medical care. Thus, a common vision and a har-
monized strategy are needed. However, there are notable dif-
ferences in health system organization and training for
dermatologists among European and even EU countries,
which will require tailored solutions. While it is difficult to
make comparisons between individual countries because of
the different response rates, a more detailed analysis of our
results regarding regional patterns is ongoing and will be
reported in the future.
The survey was addressed to dermatologists, as they are the
main users of dermoscopy across all European countries.
While the extension of dermoscopy training to general practi-
tioners or specialized nurses is considered by some coun-
tries,44 this practice is still nascent in most parts of the
European continent and could be considered for future
research.
In conclusion, owing to its large size and pan-European
reach, this study allows for an unprecedented view of der-
moscopy practice across the continent. Among up to 7500
respondents, dermoscopy appears to be a well-established
diagnostic method, widely used and well regarded by Euro-
pean dermatologists. Expanding access to the relatively inex-
pensive equipment, especially in public healthcare facilities
and establishing dermoscopy training as a key part of derma-
tology residency appear to be the main pathways, which are
both feasible and affordable, to enhance the use of this tech-
nique across European countries. In light of the rich evidence-
based benefits of dermoscopy for the early detection of skin
cancers and the noninvasive diagnosis of skin diseases, this in
turn might have far-reaching benefits for improving the land-
scape of dermatological care in Europe.
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